腹腔热灌注化疗对妇科肿瘤致恶性腹腔积液的疗效  

Clinical efficiency of intraperitoneal hyperthermic perfusion chemotherapy in the treatment of gynecological tumor patients with malignant ascites

作　　者：李津[1] 姚建[1] 张春[1] 韩玥[2] 王家富[3] LI din;YAO Jian;ZHANG Chun;HAN Yue;WANG Jiafu(Department of Combined Traditional Chinese and Western Medicine,the First Affiliated Hospital of Harbin Medical University,Harbin 150001,China;Department of Ultrasound,the First Affiliated Hospital of Harbin Medical University,Harbin 150001,China;Department of PET CT,the First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第一医院中西医结合科,哈尔滨150001 [2]哈尔滨医科大学附属第一医院超声科,哈尔滨150001 [3]哈尔滨医科大学附属第一医院PET-CT室,哈尔滨150001

出　　处：《西北药学杂志》2018年第4期542-545,共4页Northwest Pharmaceutical Journal

摘　　要：目的探讨腹腔热灌注化疗治疗妇科肿瘤导致的恶性腹腔积液的疗效。方法收集妇科肿瘤合并恶性腹腔积液的患者132例,随机分为2组,各66例,对照组行单纯腹腔灌注化疗,观察组行腹腔热灌注化疗,比较2组患者的疗效。结果治疗前,2组患者各项指标均无明显差异;治疗后观察组患者恶性腹腔积液治疗有效率为60.61%,明显高于对照组的36.36%(P<0.05);观察组患者生活质量KPS评分明显高于对照组,生活质量改善率明显高于对照组(P<0.05),血清CEA及CA125水平与CD8+T淋巴细胞水平均明显低于对照组(P<0.05),CD4+T淋巴细胞水平、CD4+/CD8+均明显高于对照组(P<0.05);2组患者不良反应发生率均未表现出明显差异。结论腹腔热灌注化疗能够有效控制妇科肿瘤导致的恶性腹腔积液,改善患者生活质量,且不增加不良反应发生风险。Objective To analyze the clinical efficiency of intraperitoneal hyperthermic perfusion chemotherapy in the treatment of gynecological tumor patients with malignant ascites.Methods 132 gynecological tumor patients with malignant ascites were selected in this research.They were randomly divided into 2 groups.66 patients in control group were treated with intraperitoneal perfusion chemotherapy,and 66 patients in observation group were treated with intraperitoneal hyperthermic perfusion chemotherapy.Clinical efficiency was compared between the 2 groups.Results Indexes before treatment showed no obvious difference.After treatment the response rate in observation group was 60.61% that was significantly higher than that 36.36% in control group（P0.05）.KPS rate in observation group was obviously higher compared with control group（P0.05）,and the improvement rate of quality of life was significantly higher than that in control group（P0.05）.CEA and CA125 were obviously lower when compared with control group（P0.05）.CD4＋ T-cells and CD4＋/CD8＋ were significantly higher than those in control group,and CD8＋ Tcells was obviously lower when compared with control group（P0.05）.The rates of adverse reactions showed no obvious difference between the 2 groups.Conclusion Intraperitoneal hyperthermic perfusion chemotherapy can effectively reduce malignant ascites of gynecological tumor patients and improve the quality of life with few adverse reactions.

关 键 词：腹腔热灌注化疗 妇科肿瘤 恶性腹腔积液 生活质量 

分 类 号：R984[医药卫生—药品]